BioCentury | Feb 16, 2019
Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
BioCentury | Oct 5, 2017
Company News

EU approval for Synthon's generic Copaxone

Synthon B.V. (Nijmegen, the Netherlands) and partner Alvogen Inc. (Pine Brook, N.J.) said a 40 mg/mL formulation of Remurel glatiramer acetate, their generic version of Copaxone from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA), received...
BioCentury | Mar 10, 2017
Company News

Sanquin Blood Supply, Synthon deal

Sanquin granted Synthon exclusive, worldwide rights to develop immuno-oncology therapeutics using Sanquin’s antibodies that modulate CD47- signal regulatory protein alpha ( SIRPA ; CD172a, SHPS-1) interaction. Sanquin referred questions to Synthon, which declined to disclose details....
BioCentury | Dec 16, 2016
Company News

MacroGenics, Synthon deal

Synthon granted MacroGenics rights to duocarmycin-based linker-drug technology to develop and commercialize preclinical MGC018 . Synthon will receive license fees and is eligible for milestones and royalties. MacroGenics will retain rights to the antibody-drug conjugate (ADC)...
BioCentury | Apr 18, 2016
Clinical News

Once-daily glatiramer acetate regulatory update

Synthon said it received European approval of its generic once-daily glatiramer acetate, a generic version of once-daily Copaxone from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA, Petah Tikva, Israel), to treat relapsing-remitting multiple sclerosis (RRMS). The company...
BioCentury | Apr 14, 2016
Company News

Synthon's generic Copaxone gets European approval

Synthon B.V. (Nijmegen, the Netherlands) said it received European approval of its 20 mg/mL glatiramer acetate, a generic version of Copaxone from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), to treat relapsing-remitting multiple sclerosis (RRMS). The company...
BioCentury | Oct 12, 2015
Clinical News

Anti-HER2-ADC: Interim Phase I data

Interim data from 12 patients with locally advanced or metastatic solid tumors in the dose-escalation part 1 of the 2-part, open-label, European Phase I SYD985.001 trial showed that 0.3, 0.6, 1.2 and 2.4 mg/kg doses...
BioCentury | Aug 10, 2015
Company News

Synthon, Pfizer autoimmune, generics news

Synthon granted Pfizer exclusive, U.S. commercialization rights to a generic version of glatiramer acetate for relapsing/remitting multiple sclerosis. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA, Petah Tikva, Israel) markets the drug as Copaxone . The deal includes Synthon’s...
BioCentury | Aug 4, 2015
Company News

Pfizer gets U.S. rights to Synthon's generic Copaxone

Synthon B.V. (Nijmegen, the Netherlands) granted Pfizer Inc. (NYSE:PFE) exclusive U.S. commercialization rights to a generic version of glatiramer acetate for relapsing/remitting multiple sclerosis. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) markets Copaxone glatiramer acetate. The deal,...
BioCentury | Dec 15, 2014
Clinical News

Anti-HER2-ADC: Phase I started

Synthon began a 2-part, open-label, international Phase I trial of IV SYD985 every 3 weeks in about 76 patients with locally advanced or metastatic solid tumors. The dose-escalation part will test SYD985 in any solid...
Items per page:
1 - 10 of 39
BioCentury | Feb 16, 2019
Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
BioCentury | Oct 5, 2017
Company News

EU approval for Synthon's generic Copaxone

Synthon B.V. (Nijmegen, the Netherlands) and partner Alvogen Inc. (Pine Brook, N.J.) said a 40 mg/mL formulation of Remurel glatiramer acetate, their generic version of Copaxone from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA), received...
BioCentury | Mar 10, 2017
Company News

Sanquin Blood Supply, Synthon deal

Sanquin granted Synthon exclusive, worldwide rights to develop immuno-oncology therapeutics using Sanquin’s antibodies that modulate CD47- signal regulatory protein alpha ( SIRPA ; CD172a, SHPS-1) interaction. Sanquin referred questions to Synthon, which declined to disclose details....
BioCentury | Dec 16, 2016
Company News

MacroGenics, Synthon deal

Synthon granted MacroGenics rights to duocarmycin-based linker-drug technology to develop and commercialize preclinical MGC018 . Synthon will receive license fees and is eligible for milestones and royalties. MacroGenics will retain rights to the antibody-drug conjugate (ADC)...
BioCentury | Apr 18, 2016
Clinical News

Once-daily glatiramer acetate regulatory update

Synthon said it received European approval of its generic once-daily glatiramer acetate, a generic version of once-daily Copaxone from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA, Petah Tikva, Israel), to treat relapsing-remitting multiple sclerosis (RRMS). The company...
BioCentury | Apr 14, 2016
Company News

Synthon's generic Copaxone gets European approval

Synthon B.V. (Nijmegen, the Netherlands) said it received European approval of its 20 mg/mL glatiramer acetate, a generic version of Copaxone from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), to treat relapsing-remitting multiple sclerosis (RRMS). The company...
BioCentury | Oct 12, 2015
Clinical News

Anti-HER2-ADC: Interim Phase I data

Interim data from 12 patients with locally advanced or metastatic solid tumors in the dose-escalation part 1 of the 2-part, open-label, European Phase I SYD985.001 trial showed that 0.3, 0.6, 1.2 and 2.4 mg/kg doses...
BioCentury | Aug 10, 2015
Company News

Synthon, Pfizer autoimmune, generics news

Synthon granted Pfizer exclusive, U.S. commercialization rights to a generic version of glatiramer acetate for relapsing/remitting multiple sclerosis. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA, Petah Tikva, Israel) markets the drug as Copaxone . The deal includes Synthon’s...
BioCentury | Aug 4, 2015
Company News

Pfizer gets U.S. rights to Synthon's generic Copaxone

Synthon B.V. (Nijmegen, the Netherlands) granted Pfizer Inc. (NYSE:PFE) exclusive U.S. commercialization rights to a generic version of glatiramer acetate for relapsing/remitting multiple sclerosis. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) markets Copaxone glatiramer acetate. The deal,...
BioCentury | Dec 15, 2014
Clinical News

Anti-HER2-ADC: Phase I started

Synthon began a 2-part, open-label, international Phase I trial of IV SYD985 every 3 weeks in about 76 patients with locally advanced or metastatic solid tumors. The dose-escalation part will test SYD985 in any solid...
Items per page:
1 - 10 of 39